Microbio Co., Ltd. (TPEX:4128)

Taiwan · Delayed Price · Currency is TWD

17.15

-0.85 (-4.72%)

At close: Jul 9, 2026

-23.78% (1Y)

Market Cap	10.59B -37.0%
Revenue (ttm)	1.94B +9.8%
Net Income	-691.94M
EPS	-1.18
Shares Out	588.17M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,630,475
Open	18.00
Previous Close	18.00
Day's Range	17.05 - 18.00
52-Week Range	14.20 - 27.50
Beta	0.43
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 10, 2026

About Microbio

Microbio Co., Ltd. researches, develops, manufactures, and trades in biotech drugs and health foods in Taiwan. It provides MS-20 for fatigue and appetite loss associated with cancer chemotherapy; and Herbiron, which reveals symptoms of iron deficiency anemia in women before menopause and relieved dysmenorrhea. The company is also involved in the sale of organic food and beverages; provision of technology development, transfer, and consulting services; and publishing of magazine, as well as offers business consulting services. Microbio Co., Ltd.... [Read more]

Industry Packaged Foods

Sector Consumer Staples

Founded 2000

Country Taiwan

Stock Exchange Taipei Exchange

Ticker Symbol 4128

Full Company Profile

Financial Performance

In 2025, Microbio's revenue was 1.89 billion, an increase of 9.94% compared to the previous year's 1.72 billion. Losses were -757.75 million, -31.16% less than in 2024.

Financial Statements